Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu
Topics & Concepts
MedicineSorafenibPembrolizumabTolerabilityInternal medicineAdverse effectHepatocellular carcinomaResponse Evaluation Criteria in Solid TumorsClinical endpointDiscontinuationGastroenterologyProgression-free survivalSurgeryOncologyPhases of clinical researchToxicityClinical trialChemotherapyCancerImmunotherapyHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCholangiocarcinoma and Gallbladder Cancer Studies